ESI Group, in Collaboration With ENSAM, Deploys in Open Source Its "Inspector" Software
3.5.2022 15:00:00 EEST | Business Wire | Press release
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Mnemo: ESI), a global simulation and virtual prototyping software partner for industry, announces the open-source release of its Inspector software; an opening for the scientific community, industrial collaboration, and innovation.
Inspector is a visual and interactive data exploration software that can analyze a large volume of data to extract useful information that can be applied in the following contexts: predictive maintenance, cybersecurity, control, and analysis of machine learning algorithms.
By making Inspector software available to as many people as possible, ESI Group continues its commitment to the industrial and academic ecosystems, offering them the possibility of working on a reliable and customizable solution to meet the technical challenges and specific needs of the community.
ENSAM (Ecole Nationale Supérieure d'Arts et Métiers) will lead the development and expansion of Inspector, as part of the continuum of sponsorship and co-creation activities already in progress between ESI Group and ENSAM. This collaboration has been reinforced with their mutual involvement in the DesCartes program led by the CNRS in Singapore, the CREATE-ID international research chair, and through the ESI - ENSAM virtual engineering laboratory.
This open-source approach has many advantages. First, it allows the community to use the software in an optimal and fast way, thus, enabling the scientific community to benefit from new functionalities adapted to the requirements of each user, as well as from security improvements. Secondly, through its approach, ESI Group wishes to offer an opportunity to benefit from a software whose reliability has been proven over the years by its customers in various industries, including Automotive and Aeronautics. “Inspector” will continue to evolve and adapt to the needs of the community thanks to the collaboration of the numerous stakeholders.
Several industry players and “Inspector” users have expressed interest and support for ESI Group's initiative to deploy its data analysis software in open source. This is the case, for example, with CNS.
Stephane Perrin, Managing Director of CNS states: "The decision taken by ESI Group is a great illustration of the Group’s dedication to the innovation and scientific ecosystem with its cutting-edge technologies. At CNS, a Network and Security expertise company, we are mobilized to ensure the future of Inspector. In addition to integrating Inspector into our continuous network auditing software suite, we will also soon offer support for the software via our business unit dedicated to innovative solutions."
Emmanuel Leroy, EVP Product, Innovation & Industry Solutions at ESI Group said: "Data and open source are the two main keywords of this new coordinated action with ENSAM. We are delighted to be able to take our collaboration a step further while contributing to academic and industrial research and innovation. "Inspector" will provide users with a tool for analyzing large volumes of data to optimize the performance of manufacturing processes. In a period where data is becoming key but remains expensive; I am convinced that this open-source release will open opportunities for industrial players, whether they are large companies or startups."
Information on how to obtain the Inspector download and installation links
The "Inspector" module can be retrieved as an archive (674MB) with the following command: sftp inspector@jibleo.com:source_code/inendi-inspector_opensource_export_2022-01-27.tgz.
The password associated with the SFTP account "inspector" is "ut!iep2E" and the checksum sha256 of the archive is d0404dd13c80ec8a4e32f406986731025881097ed03fa47a4af77827744f1000
The location of the Gitlab project from which the export was made is the following: https://gitlab.com/inendi/inspector
The software can now be installed with the following command (as indicated in the documentation on the Gitlab project homepage): flatpak install --user -y https://inendi.gitlab.io/inspector/install.flatpakref
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high-level specialists around the world and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005291/en/
Contact information
ESI - Press
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Verbatee – Press Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom